Michael Fili, MD
Endocrinology · Miami, FLNPI 1033151113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Lilly USA, LLC at 32.7% of the total. Reporting peaked in 2022 at $787 and has fallen 56.1% since, to $346 in 2025.
Across 200 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- Sanofi-aventis U.S. LLC$1K
- AbbVie$294
- Abbott$49
- Dexcom, Inc.$40
- plus $123 from 5 others
What the payments were for
- Food & beverage$4,29199%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 71 | $1,414 |
| Boehringer Ingelheim | 44 | $1,215 |
| Sanofi-aventis U.S. LLC | 60 | $1,192 |
| AbbVie | 15 | $294 |
| Abbott | 2 | $49 |
| Dexcom, Inc. | 2 | $40 |
| Merck | 2 | $37 |
| Amgen | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| EUSA Pharma (US) LLC | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
Too few endocrinology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 50 | $63,436 |
| OzempicSemaglutide | 28 | $32,260 |
| TrulicityDulaglutide | 18 | $32,238 |
| MounjaroTirzepatide | 30 | $29,945 |
| Testosterone | 59 | $17,402 |
| TradjentaLinagliptin | 12 | $14,430 |
| SynthroidLevothyroxine Sodium | 120 | $12,258 |
| Levothyroxine Sodium | 474 | $6,392 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $5,724 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 40 | $4,425 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,078 |
| Hydrocortisone | 34 | $1,609 |
| LantusInsulin Glargine,hum.Rec.Anlog | 15 | $1,034 |
| Metformin Hcl ErMetformin Hcl | 48 | $742 |
| Rosuvastatin Calcium | 42 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $1,215 | $77,86662 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,414 | $62,18348 claims |
| AbbVieSynthroid | $294 | $12,258120 claims |
| Sanofi-aventis U.S. LLCLantus | $1,192 | $1,03415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Miami
- Maria Yanez BelloMiami$0
- Vivian RoseCoral Springs$14K
- Bryan VinikBoca Raton$13K
- Renee FreedmanBoca Raton$10K
- Rolando RodriguezBoca Raton$8K
- Carlos ZapataTallahassee$5K
- Rodolfo Perez LopezHialeah$3K
- Mohammad BaigTampa$2K
- Myat MyintHudson$182
- Kathryn JonesBoca Raton$142
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.